Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA   US9216591084

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2014 10/17/2014 10/20/2014 10/21/2014 10/22/2014 Date
10.225(c) 10.08(c) 10.56(c) 10.19(c) 10.03(c) Last
605 841 422 062 422 104 263 237 328 393 Volume
+8.09% -1.42% +4.76% -3.50% -1.57% Change
More quotes
Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.Its product portfolio includes Fanapt and Tasimelteon.The Fanapt product is a compound for the treatment of schizophrenia, the... 
Surperformance© rating of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More about the company
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 46,5 M
EBIT 2014 -65,8 M
Net income 2014 -76,1 M
Debt 2014 -
Yield 2014 -
Sales 2015 89,5 M
EBIT 2015 -58,2 M
Net income 2015 -62,9 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 7,31x
Capi. / Sales 2015 3,80x
Capitalization 340 M
More Financials
Latest news on VANDA PHARMACEUTICALS INC.
10/14 VANDA PHARMACEUTICALS : to Announce Third Quarter 2014 Financial Results on Octo..
09/22 VANDA PHARMACEUTICALS : Amendments to Articles of Inc. or Bylaws; Change in Fisc..
08/14DJJOHN PAULSON : Paulson & Co. Opens Positions in Covidien, DirecTV and Allergan
08/08 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
08/07 VANDA PHARMACEUTICALS : Results of Operations and Financial Condition, Financial..
08/07 VANDA PHARMACEUTICALS : Reports Second Quarter 2014 Results
07/30 VANDA PHARMACEUTICALS : Patent Issued for Treatment of Circadian Rhythm Disorder..
07/23 VANDA PHARMACEUTICALS : Assigned Patent
07/17 VANDA PHARMACEUTICALS : to Announce Second Quarter 2014 Financial Results on Aug..
07/17 VANDA PHARMACEUTICALS : Other Events (form 8-K)
06/16 VANDA PHARMACEUTICALS : Other Events (form 8-K)
06/12 VANDA PHARMACEUTICALS : European Medicines Agency Accepts HETLIOZ™ tasimel..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF